Discover
IMUX
Immunic, Inc.
10.62
1 x 10.57
1 x 10.74
bid
ask
+
0.27
2.61%
1 @ 07:30 PM
10.63 +0.01 (0.09%)
| Ytd | 98.88% | |
| 1y | 26.43% |
10.21
day range
10.74
5.10
52 week range
16.90
| Open | 10.30 | Prev Close | 10.35 | Low | 10.21 | High | 10.74 | Mkt Cap | 144.90M |
| Vol | 404.00K | Avg Vol | 215.00K | EPS | -3.55 | P/E | N/A | Forward P/E | -1.67 |
| Beta | 1.88 | Short Ratio | 4.69 | Inst. Own | 64.85% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-12 | 50-d Avg | 14.36 | 200-d Avg | 11.19 | 1yr Est | 12.79 |
| Income Statement | |||
| Operating Expenses | 35.33M | ||
| Research and Development Expense | 25.93M | ||
| Selling, General and Administrative Expense | 9.40M | ||
| Operating Income | -35.33M | ||
| Net Income | -34.10M | ||
| Net Income Common Stock | -34.10M | ||
| Net Income Common Stock (USD) | -34.10M | ||
| Consolidated Income | -34.10M | ||
| Earnings per Basic Share | -0.80 | ||
| Earnings per Basic Share (USD) | -0.80 | ||
| Earnings per Diluted Share | -0.80 | ||
| Earning Before Interest & Taxes (EBIT) | -34.10M | ||
| Earning Before Interest & Taxes (USD) | -34.10M | ||
| Weighted Average Shares | 42.51M | ||
| Weighted Average Shares Diluted | 42.51M | ||
| Balance Sheet | |||
| Cash and Equivalents | 155.10M | ||
| Cash and Equivalents (USD) | 155.10M | ||
| Current Assets | 157.83M | ||
| Property, Plant & Equipment Net | 1.34M | ||
| Total Assets | 159.17M | ||
| Total Debt | 328.00K | ||
| Current Liabilities | 31.26M | ||
| Debt Non-Current | 328.00K | ||
| Total Liabilities | 31.59M | ||
| Accumulated Retained Earnings (Deficit) | -675.26M | ||
| Accumulated Other Comprehensive Income | 2.77M | ||
| Shareholders Equity | 127.58M | ||
| Shareholders Equity (USD) | 127.58M | ||
| Assets Non-Current | 1.34M | ||
| Total Debt (USD) | 328.00K | ||
| Liabilities Non-Current | 328.00K | ||
| Trade and Non-Trade Payables | 12.67M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 243.00K | ||
| Net Cash Flow from Financing | 118.00K | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | -31.53M | ||
| Capital Expenditure | -249.00K | ||
| Issuance (Purchase) of Equity Shares | 118.00K | ||
| Net Cash Flow from Investing | -249.00K | ||
| Net Cash Flow from Operations | -31.00M | ||
| Effect of Exchange Rate Changes on Cash | -402.00K | ||
| Share Based Compensation | 6.78M | ||